Masimo develops advanced noninvasive monitoring technologies used by hospitals and healthcare providers worldwide.

Apple's current blood oxygen sensing implementation in the U.S. does not infringe on patents owned by Masimo and Apple will not face a revived import ban, a U.S. International Trade Commission judge ...

A US appeals court has found in favor of Masimo in its fight against Apple over pulse oximetry patents, but in the court that ...

There are two new developments in Apple’s ongoing legal battle with health technology company Masimo over the Apple Watch’s ...

The United States Court of Appeal for the Federal Circuit has just affirmed the original ITC ruling in the Masimo vs Apple legal battle, reports IPFray. That means Apple’s appeal was unsuccessful.

Danaher buys Masimo for $180 per share. Explore the details of this $9.9B healthcare acquisition and its impact on medical ...

The decision, made public on Thursday, concludes that Apple's latest implementation of pulse-oximetry functionality falls outside the scope of Masimo's asserted rights. The full ITC commission ...

Masimo (NASDAQ: MASI) will release fourth quarter and full year 2025 financial results for the period ended January 3, 2026, after the market closes on Thursday, February 26, 2026. The conference call ...

WASHINGTON, Feb. 17, 2026 /PRNewswire/ -- Danaher Corporation (NYSE: DHR), a global science and technology innovator, announced today that it has entered into a definitive agreement to acquire Masimo ...